

Special Issue

Advances in Urothelial Cancer Volume II

Message from the Guest Editors

The use of immune checkpoint inhibitors, particularly with antibodies directed against programmed cell death 1 protein (PD-1) or its ligand (PD-L1), has led to important advances in the treatment of metastatic urothelial cancer and been tested in the early stages of bladder cancer. However, only a small number of patients respond to checkpoint inhibitors. Therefore, attempts are being made to develop biomarkers that could help to identify urothelial cancer patients who are likely to respond to these drugs. As a type of targeted therapy, therapeutic agents such as enfortumab vedotin, an antibody-drug conjugate designed to treat Nectin-4 expressing cancer, and erdafitinib, a small molecule inhibitor of fibroblast growth factor receptor, have been accepted in clinical studies on metastatic bladder cancer. In this Special Issue on “Advances in the Urothelial Cancer Volume II”, we will include the information and available data regarding molecular classification, diagnosis, immunotherapy, various targeted agents, and antibody-drug conjugates that have recently shown promising results against urothelial cancer.

Guest Editors

Dr. Ho Kyung Seo

Prof. Dr. Eu Chang Hwang

Dr. Whi-An Kwon

Deadline for manuscript submissions

closed (31 October 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/153422

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).